Press Releases



    • MAY 19 2020

    AACR Presentations Highlight Preclinical Efficacy of Impridones in Molecularly-Selected Tumors

    Philadelphia, PA (May 19, 2020) – Oncoceutics, Inc. announced that the latest research findings with ONC201 and its novel class of imipridones will be presented at the 2020 annual meeting of the American Association of Cancer Research (AACR) on June 22-24, 2020. The research presented at AACR highlights the antitumor and cancer prevention activity of

    • MAY 05 2020

    Oncoceutics Commemorates Brain Tumor Awareness Month

    Philadelphia, PA (May 5, 2020) – Oncoceutics, a clinical-stage drug discovery and development company, commemorates Brain Tumor Awareness Month this May and expresses its support for all those affected by brain tumors. Brain tumors remain one of the greatest current health challenges as there are limited treatment options for patients, and prognoses continue to be

    • APR 07 2020

    Co-Founder and CEO Wolfgang Oster Departs from Oncoceutics

    Philadelphia, PA (April 7, 2020) – Oncoceutics, Inc., a clinical-stage drug discovery and development company with a novel class of compounds called imipridones, announced today that Wolfgang Oster, MD, PhD, one of the company’s co-founders and Chief Executive Officer, has left the company effective April 3 as part of a leadership change.  He has also

    • APR 01 2020

    Phase I/II Clinical Study of ONC201 Begins in Japan

    Philadelphia, PA (April 1, 2020) – Oncoceutics, Inc., announced that it was informed by its Japanese licensee, Ohara Pharmaceutical Co., Ltd., of the initiation of a Phase I/II clinical study of OP-10 (the Japanese name for ONC201) in Japan and the administration of the drug to the first patient.  ONC201 is a novel small molecule